thyroxine has been researched along with Cutaneous T-Cell Lymphoma in 4 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies." | 8.83 | Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. ( Assaf, C; Bagot, M; Dummer, R; Duvic, M; Gniadecki, R; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S, 2006) |
| "Bexarotene is a specific retinoid X receptor agonist that has been used for the treatment of cutaneous T-cell lymphoma (CTCL)." | 8.12 | Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. ( Cayrol, F; Cerchietti, L; Cremaschi, GA; Debernardi, M; Díaz Flaqué, MC; Magro, C; Marullo, R; Mulvey, E; Paulazo, A; Phillip, JM; Revuelta, MV; Ruan, J; Sterle, H; Zamponi, N, 2022) |
| "Bexarotene-induced central hypothyroidism (CH), for which levothyroxine (LT4) replacement is recommended, has been shown to be caused by pituitary but not hypothalamic disorder experimentally, though the underlying mechanism in humans remains unclear." | 8.12 | Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. ( Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S, 2022) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 5.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| "Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies." | 4.83 | Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. ( Assaf, C; Bagot, M; Dummer, R; Duvic, M; Gniadecki, R; Knobler, R; Ranki, A; Schwandt, P; Whittaker, S, 2006) |
| "Bexarotene is a specific retinoid X receptor agonist that has been used for the treatment of cutaneous T-cell lymphoma (CTCL)." | 4.12 | Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. ( Cayrol, F; Cerchietti, L; Cremaschi, GA; Debernardi, M; Díaz Flaqué, MC; Magro, C; Marullo, R; Mulvey, E; Paulazo, A; Phillip, JM; Revuelta, MV; Ruan, J; Sterle, H; Zamponi, N, 2022) |
| "Bexarotene-induced central hypothyroidism (CH), for which levothyroxine (LT4) replacement is recommended, has been shown to be caused by pituitary but not hypothalamic disorder experimentally, though the underlying mechanism in humans remains unclear." | 4.12 | Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients. ( Emoto, M; Hayashi, D; Imanishi, Y; Inaba, M; Kurajoh, M; Miyaoka, D; Morita, A; Nagata, Y; Tateishi, C; Toi, N; Tsuruta, D; Yamada, S, 2022) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 1.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cayrol, F | 1 |
| Revuelta, MV | 1 |
| Debernardi, M | 1 |
| Paulazo, A | 1 |
| Phillip, JM | 1 |
| Zamponi, N | 1 |
| Sterle, H | 1 |
| Díaz Flaqué, MC | 1 |
| Magro, C | 1 |
| Marullo, R | 1 |
| Mulvey, E | 1 |
| Ruan, J | 1 |
| Cremaschi, GA | 1 |
| Cerchietti, L | 1 |
| Toi, N | 1 |
| Kurajoh, M | 1 |
| Miyaoka, D | 1 |
| Nagata, Y | 1 |
| Yamada, S | 1 |
| Imanishi, Y | 1 |
| Hayashi, D | 1 |
| Tateishi, C | 1 |
| Inaba, M | 1 |
| Tsuruta, D | 1 |
| Morita, A | 1 |
| Emoto, M | 1 |
| Scarisbrick, JJ | 1 |
| Morris, S | 1 |
| Azurdia, R | 1 |
| Illidge, T | 1 |
| Parry, E | 1 |
| Graham-Brown, R | 1 |
| Cowan, R | 1 |
| Gallop-Evans, E | 1 |
| Wachsmuth, R | 1 |
| Eagle, M | 1 |
| Wierzbicki, AS | 1 |
| Soran, H | 1 |
| Whittaker, S | 2 |
| Wain, EM | 1 |
| Assaf, C | 1 |
| Bagot, M | 1 |
| Dummer, R | 1 |
| Duvic, M | 1 |
| Gniadecki, R | 1 |
| Knobler, R | 1 |
| Ranki, A | 1 |
| Schwandt, P | 1 |
1 review available for thyroxine and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Topics: Anticarcinogenic Agents; Bexarotene; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; | 2006 |
3 other studies available for thyroxine and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Bexarotene; Humans; Integrin alphaVbeta3; Lymphoma, | 2022 |
Bexarotene-induced central hypothyroidism assessed by TRH stimulation test in cutaneous T-cell lymphoma patients.
Topics: Bexarotene; Humans; Hypothyroidism; Lymphoma, T-Cell, Cutaneous; Retrospective Studies; Skin Neoplas | 2022 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, | 2013 |